Bristol Myers Squibb (CELG-RI) Long-Term Deferred Tax (2009 - 2026)

Bristol Myers Squibb has disclosed Long-Term Deferred Tax across 18 years of filings, most recently posting $5.2 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 29.5% year-over-year to $5.2 billion; the TTM figure through Mar 2026 stood at $5.2 billion (up 29.5% YoY), while the FY2025 annual figure was $5.4 billion, up 26.96% from the prior year.
• Long-Term Deferred Tax declined to $5.2 billion in Q1 2026, from $5.4 billion in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for CELG-RI reached as high as $5.4 billion in Q4 2025 and fell as low as $1.3 billion in Q1 2023.
• The 5-year median for Long-Term Deferred Tax is $2.8 billion (2023), against an average of $3.0 billion.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax slipped 7.12% — and 2024, when it surged 138.38%.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.3 billion in 2022, then surged by 105.95% to $2.8 billion in 2023, then surged by 53.03% to $4.2 billion in 2024, then advanced by 26.96% to $5.4 billion in 2025, then retreated by 3.76% to $5.2 billion in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $5.2 billion, $5.4 billion, and $5.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.